Paper25754535
Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.
Liao YJ and 9 others. Int J Cancer, 2015. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications. Papers, record 25754535. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25754535
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carrier Proteins | Major topic |
| Glycoproteins | Major topic |
| Liver Neoplasms | Major topic |
| MAP Kinase Signaling System | Major topic |
| Animals | |
| Carcinoma, Hepatocellular | |
| Cell Line | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Disease Progression | |
| Down-Regulation | |
| Female | |
| HEK293 Cells | |
| Hep G2 Cells | |
| Humans | |
| Mice | |
| Mice, Inbred C57BL | |
| Mice, Inbred NOD | |
| Mice, Knockout | |
| Mice, SCID | |
| Survival Rate | |
| Vesicular Transport Proteins | |
| alpha-Fetoproteins |
Source PubMed
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42564225 | A single-cell sequencing-based prognostic model reveals HLA-DRA, NPC2, and PRPF38B as immune-regulatory tumor suppressors in non-small cell lung cancer. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42564225 | PubMed |
| 41816293 | NPC2 suppresses osteolytic metastasis in lung adenocarcinoma via the AKT/mTOR pathway and tumor-osteoclast crosstalk. | iScience | 2026 | https://conductscience.org/library/papers/41816293 | PubMed |
| 41624864 | Multi-omics integration and machine learning identify NPC2 as a prognostic and treatment-responsive regulator in lung adenocarcinoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/41624864 | PubMed |
| 40302802 | Cholesterol metabolism-related genes predict immune infiltration and prognosis in gastric cancer patients. | J Cancer | 2025 | https://conductscience.org/library/papers/40302802 | PubMed |
| 38586328 | Advances in prognostic models for osteosarcoma risk. | Heliyon | 2024 | https://conductscience.org/library/papers/38586328 | PubMed |
| 38402299 | Development of a CD8+ T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing. | Sci Rep | 2024 | https://conductscience.org/library/papers/38402299 | PubMed |
| 38216938 | Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma. | Virol J | 2024 | https://conductscience.org/library/papers/38216938 | PubMed |
| 38071335 | Dysregulated cholesterol regulatory genes in hepatocellular carcinoma. | Eur J Med Res | 2023 | https://conductscience.org/library/papers/38071335 | PubMed |
| 38001127 | Prognostic significance of high NPC2 expression in gastric cancer. | Sci Rep | 2023 | https://conductscience.org/library/papers/38001127 | PubMed |
| 37541978 | Exploring the diagnostic value, prognostic value, and biological functions of NPC gene family members in hepatocellular carcinoma based on a multi-omics analysis. | Funct Integr Genomics | 2023 | https://conductscience.org/library/papers/37541978 | PubMed |
| 36819514 | Construction of a novel mRNAsi-related risk model for predicting prognosis and immunotherapy response in osteosarcoma. | Ann Transl Med | 2023 | https://conductscience.org/library/papers/36819514 | PubMed |
| 35053588 | Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35053588 | PubMed |
| 34445279 | Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34445279 | PubMed |
| 34138521 | Hepatocellular carcinoma as a complication of Niemann-Pick disease type C1. | Am J Med Genet A | 2021 | https://conductscience.org/library/papers/34138521 | PubMed |
| 33425993 | Identification and Development of a Novel 4-Gene Immune-Related Signature to Predict Osteosarcoma Prognosis. | Front Mol Biosci | 2020 | https://conductscience.org/library/papers/33425993 | PubMed |
| 32575795 | Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma. | Molecules | 2020 | https://conductscience.org/library/papers/32575795 | PubMed |
| 31779269 | HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31779269 | PubMed |
| 30923463 | MKP-4 suppresses hepatocarcinogenesis by targeting ERK1/2 pathway. | Cancer Cell Int | 2019 | https://conductscience.org/library/papers/30923463 | PubMed |
| 29874879 | Niemann-Pick Type C2 Protein Regulates Free Cholesterol Accumulation and Influences Hepatic Stellate Cell Proliferation and Mitochondrial Respiration Function. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29874879 | PubMed |
| 29522534 | Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. | PLoS One | 2018 | https://conductscience.org/library/papers/29522534 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| MAP2K1 | 5604 | PubTator's text mining | https://conductscience.org/library/genes/5604 | NCBI Gene |
| MAP2K2 | 5605 | PubTator's text mining | https://conductscience.org/library/genes/5605 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK3 | 5595 | PubTator's text mining | https://conductscience.org/library/genes/5595 | NCBI Gene |
| MIR7-3HG | 284424 | PubTator's text mining | https://conductscience.org/library/genes/284424 | NCBI Gene |
| NPC2 | 10577 | PubTator's text mining | https://conductscience.org/library/genes/10577 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25754535
GET https://conductscience.org/api/papers/v1/25754535/cited_by?page=2